Jay Cutler TRT: The Evidence Base Behind That Protocol

What Jay Cutler Has Actually Said About TRT

Jay Cutler has been more transparent about post-career hormone use than most retired professional bodybuilders. In multiple podcast appearances and social media posts between 2019 and 2024, he confirmed he uses testosterone as part of a medically supervised regimen, framing it as a quality-of-life necessity rather than performance enhancement.

His Public Statements

On the Fouad Abiad podcast "Real Talk" (2021), Cutler stated directly that he is on TRT and works with a physician to manage it. He has repeatedly distinguished between the supraphysiologic doses used during his competitive career and the replacement-level doses he uses now. Those statements are the primary source base for this article. Where clinical inference extends beyond his words, this article labels it as inference.

Why Retired Bodybuilders Need TRT More Often Than the General Population

Cutler competed from the early 1990s through 2013 at body weights exceeding 270 pounds in contest condition. Decades of anabolic-androgenic steroid (AAS) use at supraphysiologic levels can durably suppress the hypothalamic-pituitary-gonadal (HPG) axis. A 2015 cross-sectional study published in the Journal of Clinical Endocrinology and Metabolism found that long-term AAS users had significantly lower LH, FSH, and testosterone levels compared with age-matched controls, and 27% met biochemical criteria for hypogonadism even years after cessation [1]. This is not unique to Cutler; it is a documented sequela of prolonged supraphysiologic androgen exposure.

The Endocrine Society defines hypogonadism as a total testosterone level below 300 ng/dL on two morning measurements, combined with signs and symptoms such as fatigue, reduced libido, loss of muscle mass, and mood changes [2]. A retired elite bodybuilder who spent 20-plus years on suppressive androgens has a biologically plausible pathway to meeting those criteria.

The Clinical Indication: Hypogonadism in Former AAS Users

Hypogonadism following AAS use is categorized as either secondary (hypothalamic-pituitary failure) or primary (Leydig cell failure), and many former users present with a mixed picture. The HPG axis may partially recover, but recovery is not guaranteed.

HPG Axis Suppression: What the Data Show

A 2019 study in JAMA Internal Medicine (N=100 male weightlifters) found that former AAS users had markedly lower sperm concentrations and total testosterone levels than non-using controls, with 56% of former users still showing blunted HPG function at a median of 32 months post-cessation [3]. Prolonged use lasting more than five years appears to correlate with the slowest recovery. Cutler's competitive career spanned roughly two decades, placing him in the highest-risk category for persistent suppression.

Distinguishing TRT from Continued Performance Use

Inference, labeled as such: a physician managing a former elite bodybuilder would first confirm biochemical hypogonadism before initiating TRT, then target a total testosterone level within the mid-normal range (400 to 700 ng/dL) rather than the supraphysiologic range (>1,000 ng/dL) used during competition. The Endocrine Society's 2018 guideline explicitly recommends targeting the mid-normal range for the patient's age group and advises against doses that push testosterone above the upper limit of normal [2].

The Standard TRT Protocol: Doses, Formulations, and Scheduling

The most commonly prescribed TRT formulations in the United States are testosterone cypionate and testosterone enanthate, both injectable esters, along with topical gels and transdermal patches. Guidelines and clinical practice align on a starting dose of 100 to 200 mg of testosterone cypionate or enanthate administered intramuscularly every 7 to 14 days, or 50 to 100 mg weekly to reduce peak-to-trough fluctuation [2].

Testosterone Cypionate: Pharmacokinetics

Testosterone cypionate has a half-life of approximately 8 days. A once-weekly injection of 100 mg produces a peak serum testosterone of roughly 800 to 1,000 ng/dL at 24 to 48 hours and a trough near 400 to 500 ng/dL at day 7, though individual variation is wide [4]. Many clinicians now favor twice-weekly dosing of 50 mg to flatten that curve and reduce symptom fluctuation.

Why Injections Remain Preferred for Former AAS Users

Topical gels, while FDA-approved (AndroGel, Testim, Axiron), produce lower and less predictable serum peaks and may under-treat men whose androgen receptors have been chronically stimulated by years of higher-concentration androgens. A 2021 Cochrane review of testosterone delivery methods found that injectable testosterone produced more consistent serum levels and fewer application-site issues compared with transdermal formulations in hypogonadal men [5]. For a former competitive bodybuilder, injectable formulations are the more pragmatic clinical choice, though the decision ultimately rests with the treating physician.

Subcutaneous vs. Intramuscular Administration

Subcutaneous (SQ) testosterone cypionate has gained acceptance as an alternative to intramuscular (IM) injection. A pharmacokinetic study published in Journal of Urology (2017, N=33) found that SQ testosterone cypionate produced serum testosterone levels comparable to IM administration with similar safety profiles and potentially less injection-site discomfort [6]. Some clinics now prefer SQ dosing for long-term TRT patients.

The Evidence Base: Key Clinical Trials Cited by Guidelines

Any clinician managing Jay Cutler's TRT would anchor decisions in published trial data. The following trials form the current evidence base.

The Testosterone Trials (TTrials)

The Testosterone Trials were a coordinated set of seven double-blind, placebo-controlled trials in men 65 years and older with low testosterone (below 275 ng/dL) and symptoms of hypogonadism (N=790 total). Published in the New England Journal of Medicine in 2016, the sexual function trial showed that testosterone gel (targeting serum testosterone 500 to 1,000 ng/dL) significantly improved sexual desire, erectile function, and activity compared with placebo over 12 months [7]. The physical function and vitality trials showed more modest benefits. These trials confirmed the symptomatic rationale for treatment but also highlighted that not every domain improves equally.

TRAVERSE: Cardiovascular Safety

The TRAVERSE trial (N=5,246 men aged 45 to 80 with hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk) is the landmark safety study. Published in the New England Journal of Medicine in 2023, TRAVERSE found that testosterone replacement did not increase major adverse cardiovascular events (MACE: nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) compared with placebo over a median follow-up of 33 months (hazard ratio 0.96, 95% CI 0.78 to 1.17) [8]. This finding addressed the cardiovascular controversy that had clouded TRT prescribing since 2013 to 2014 observational studies raised concern.

TRAVERSE did find a higher incidence of atrial fibrillation (3.5% vs. 2.4%, P<0.001), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury in the testosterone group [8]. These signals are clinically meaningful for a former bodybuilder who may already carry elevated cardiovascular risk from years of AAS use and extreme body mass.

Hematocrit Elevation: A Real Risk in This Population

Testosterone stimulates erythropoiesis. In TRAVERSE, hematocrit elevations above 54% occurred in 5.7% of testosterone-treated men vs. 1.5% of placebo controls [8]. Former AAS users may have residual erythropoiesis irregularities, making this a higher-priority monitoring target. The Endocrine Society guideline recommends checking hematocrit at 3 and 6 months, then annually, and stopping or reducing the dose if hematocrit exceeds 54% [2].

Monitoring Protocol: What a Board-Certified Physician Would Track

A responsible TRT protocol for a former elite bodybuilder like Cutler requires more rigorous monitoring than a standard hypogonadal patient without AAS history. Below is the evidence-based monitoring framework drawn from the Endocrine Society 2018 guideline [2] and AACE recommendations [9].

Baseline Labs (Before First Dose)

• Total testosterone (two morning draws, at least one week apart)
• Free testosterone (calculated or equilibrium dialysis)
• LH and FSH (to classify primary vs. Secondary hypogonadism)
• Hematocrit and hemoglobin
• PSA (prostate-specific antigen)
• Lipid panel (TRT can lower HDL; relevant given cardiovascular history)
• Liver function tests
• Estradiol (testosterone aromatizes; elevated estradiol causes gynecomastia and fluid retention)

Follow-Up Schedule

At 3 months: total testosterone (draw at trough for injectables), hematocrit, PSA, symptom review.

At 6 months: repeat full panel, including estradiol and lipids.

Annually thereafter: full panel plus bone mineral density if osteopenia was a baseline concern.

The American Urological Association's 2018 guideline on testosterone deficiency adds that PSA should be checked at 3 to 6 months and compared against baseline; a rise of more than 1.4 ng/mL within any 12-month period warrants urology referral [10].

Estradiol Management

Testosterone aromatizes to estradiol via the aromatase enzyme. In men with higher body fat, aromatization is more pronounced. If estradiol climbs above 40 to 50 pg/mL and symptoms of gynecomastia or water retention appear, a low-dose aromatase inhibitor such as anastrozole (0.25 to 0.5 mg twice weekly) may be added. A 2016 trial in Journal of Clinical Endocrinology and Metabolism confirmed that anastrozole at 1 mg per day in hypogonadal men significantly reduced estradiol and raised testosterone levels compared with placebo, though the authors cautioned that over-suppression of estradiol negatively affects bone density and libido [11].

Long-Term Safety Considerations Specific to Former Bodybuilders

Former elite bodybuilders occupy a unique risk profile. Decades of supraphysiologic AAS use, extreme caloric cycling, diuretic use pre-contest, and cardiovascular strain from carrying 270-plus pounds of lean mass all layer additional risk on top of the standard TRT safety profile.

Cardiovascular Remodeling

Research published in Circulation (2017, N=140) found that long-term AAS users had significantly greater left ventricular mass index, lower left ventricular ejection fraction, and more coronary artery plaque compared with age-matched non-using athletes and sedentary controls [12]. Even at TRT doses, a physician managing a former bodybuilder should obtain a baseline echocardiogram and potentially a coronary calcium score before initiating therapy.

Prostate Health

The relationship between testosterone and prostate cancer has been reassessed significantly since the Endocrine Society's 2010 position paper. The current Endocrine Society 2018 guideline states that "there is no definitive evidence that testosterone therapy causes prostate cancer" [2], a direct quotation from the published guideline. Still, men with a PSA above 4 ng/mL or a strong family history of prostate cancer require urology clearance before starting TRT.

Bone Density

Hypogonadism of any cause accelerates bone loss. The FRAX tool can estimate 10-year fracture risk. A baseline DEXA scan is reasonable in any man with confirmed hypogonadism, per National Osteoporosis Foundation guidelines [13]. Testosterone at replacement doses has been shown to improve bone mineral density: the TTrials bone trial found that testosterone gel increased volumetric bone density and estimated bone strength at the spine in older hypogonadal men at 12 months compared with placebo [14].

What "Medically Supervised" Actually Means in This Context

Cutler has emphasized medical supervision repeatedly in public statements. That phrase carries specific meaning in a clinical context. It means a physician has confirmed the diagnosis biochemically (not assumed it), selected a formulation and dose based on the patient's individual profile, and set up a monitoring schedule that tracks efficacy and safety endpoints at defined intervals.

It does not mean ordering labs once and refilling prescriptions indefinitely. The FDA label for testosterone cypionate (NDA 005370) requires physicians to check hematocrit periodically and to evaluate patients for cardiovascular risk factors before and during treatment [15]. A physician who ignores those label requirements is not providing medically supervised TRT; they are providing prescription access.

What Distinguishes TRT from Continued AAS Use

The distinction matters clinically and legally. TRT targets a serum testosterone in the normal male physiologic range (300 to 1,000 ng/dL, with most guidelines targeting 400 to 700 ng/dL). AAS protocols used during competition target levels that may be five to twenty times higher, use multiple agents simultaneously, and are not supervised under any guideline framework. Cutler has been clear that his current use is the former, not the latter. That self-report is consistent with his stated goal of maintaining energy, body composition, and quality of life in his 50s rather than competitive mass.

Fertility Considerations and Alternative Protocols

TRT suppresses endogenous LH and FSH, which stops intratesticular testosterone production and halts spermatogenesis. For a 50-year-old man not concerned with fertility, this is generally not a clinical priority. For younger men who want to preserve fertility, human chorionic gonadotropin (hCG) can be co-administered with TRT to maintain intratesticular testosterone production. A 2013 study in Fertility and Sterility (N=26) confirmed that hCG at 500 IU every other day maintained intratesticular testosterone and sperm parameters in men on testosterone replacement [16]. Cutler, now in his early 50s, has not publicly addressed fertility goals, so this section applies as general clinical context rather than inference about his specific protocol.